Entitled ‘Managing mitral valve disease from start to finish’, the course will account for four hours’ CPD split into six short bite-size sessions which can be completed at your own pace.
The sessions are presented by Dr Mike Martin MVB DVC MRCVS, and business thought leader, Dr Alison Lambert BVSc CMRS MRCVS. They consist of a practical review of MVD both pre-clinically and clinically and how to diagnose and stage it following the new 2019 American College of Veterinary Internal Medicine (ACVIM) Consensus guidelines.
The course also includes tips on how to treat and manage dogs with MVD with diuretic management; a step-by-step guide to treatment options for acute and long-term management of congestive heart failure and how to troubleshoot problem congestive heart failure cases.
There's also a bonus ‘Communicating Cardiology’ session which looks at how to communicate the heart disease journey to owners.
To register for the course visit www.veterinarywebinars.com/mvd-reg.
Ceva will donate £2 for every veterinary professional completing the course throughout February and March 2021 to Vetlife, which provides support to the veterinary community and their families who have emotional, health or financial concerns.
Mr Ng faced seven charges:
Mr Ng admitted some aspects of the charges against him, including that he had deleted two patient records and that this was dishonest and misleading.
The Committee then determined the facts of the rest of the charges after hearing evidence from witnesses and Mr Ng himself, as well as expert witnesses.
Having considered all the evidence, it determined which elements of the charges were proved, and which were not.
The Committee then considered whether the admitted and charges found proved amounted to serious professional misconduct.
In doing so it considered that the charges against Mr Ng fell into three broad categories – deficiencies in clinical care, deficiencies in record keeping, and dishonesty.
In respect of all three, it found the admitted and charges found proved amounted to serious professional misconduct.
In terms of aggravating factors, the Committee found that Mr Ng’s conduct had directly caused harm to animals and also created risk of further harm, and noted that there were three instances of dishonesty.
Paul Morris, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee noted that there were three instances of dishonest behaviour in relation to clinical records.
"The amendment of the clinical record in the labradoodle’s case was particularly serious.
"This alteration was made at a time when the respondent knew that the owner was dissatisfied with the treatment the dog had received and was complaining about the lack of therapeutic intervention.
"The alteration presented a false account of the owner’s attitude towards immediate therapeutic intervention.
"Conduct of this kind was liable to damage trust in the profession.”
In mitigation, the Committee took into account the sense of pressure Mr Ng felt following a financial dispute with his relative in respect of the veterinary practice, his long career as a veterinary surgeon and the high regard with which he was held by those who provided testimonials on his behalf.
The Committee acknowledged Mr Ng’s assertions that he now understood his failings and his expressions of remorse for the harm he had caused and that these indicated the beginnings of insight.
However, in respect of the clinical deficiencies, the Committee found that various aspects of Mr Ng’s approach to treating conditions such as diabetes and cherry eye were inadequate and out-of-date, and that there was little in his continuing professional development (CPD) record or his statements to suggest he had attempted to improve these deficiencies.
Ultimately, the Committee found that Mr Ng’s conduct was so serious that removal from the Register was the most appropriate sanction.
Paul Morris added: “The Committee has concluded that the respondent’s behaviour was fundamentally incompatible with being a veterinary surgeon.
"In view of the nature and gravity of the Committee’s findings in this case, removal from the Register is necessary to ensure the protection of animals and the maintenance of public confidence in the profession and the regulatory process.”
www.rcvs.org.uk/disciplinary
Zoetis says the Vetscan OptiCell represents a significant leap forward in technology and offers meaningful time, cost and space savings for veterinary healthcare teams, contributing to better patient outcomes and a more efficient clinic workflow.
It uses cell-focusing and AI-powered classification technology for CBC analysis, delivering a claimed lab quality accuracy at the point of care.
Dr. Richard Goldstein, DVM, DACVIM, DECVIM-CA, Global Chief Medical Officer and Head of Medical Affairs at Zoetis said: “Vetscan OptiCell delivers high-quality results, enables improved efficiency, and provides a compact footprint.
"For the first time, we are able to use advanced AI image recognition technology to characterise the blood cells instead of relying on their size or other physical parameters.”
Pre-orders will be available in the UK later this year.
Carl's article: 'Are you using a safety checklist in your practice?', focuses on the benefits of introducing a safety checklist in practice to reduce patient morbidity, mortality and to improve communication between members of the veterinary team.
He explains how a checklist helps eliminate the need to memorise every single step of a protocol and self-limit any errors that may eventually lead to a fatal or near-fatal incident, and how it should contain a limited number of elements, allow quick completion and most importantly be relevant to the situation.
The article includes information on how to introduce a safety checklist, steps to consider and how to use one in practice.
It also contains links to downloadable tools including the Association of Veterinary Anaesthetists (AVA) safety checklist and implementation booklet and information on the association’s ‘Safer Anaesthesia Project’. An editable safety checklist will also be available to download from the ‘Anaesthesia1ST’ blog that practices can adapt to their own requirements.
Richard Beckwith, country manager of Jurox (UK) said: "Our hugely popular Anaesthesia1ST newsletter features state-of-the-art, practical and easy to read articles to help veterinary professionals deliver 1ST class anaesthesia to all patients. Our latest edition will challenge practices to consider safety checklists as an essential part of their pre-anaesthetic routine in order to reduce the risk of mistakes."
To sign up to the Anaesthesia1ST newsletter visit the Alfaxan website – www.alfaxan.co.uk, contact your local Jurox technical sales representative or email Jurox at info@jurox.co.uk.
Divided into four modules, the course explores vaccines and the immune system; current and emerging strains of Leptospirosis; a practical insight into infectious disease and vaccination and the importance of getting early socialisation right.
Professor Sarah Gilbert from the Jenner Institute in Oxford presents the first CPD module. She is followed by Dr Paul Burr from Biobest Laboratories, Alan Radford from the University of Liverpool and Jon Bowen of the RVC.
John Toole, Zoetis Product Manager said: "We were extremely privileged to be able to work with such an eminent group of key opinion leaders for this CPD course. We hope participants find the interview video style of this course dynamic and insightful. Users can also find an additional module on our dog vaccine Versican Plus and how it helps meet today’s infectious disease challenges as discussed by our industry experts."
To take part in this new CPD, vets simply need to register at www.vetsupportplus.co.uk where they will be able to access all the free Zoetis learning content and receive a certificate once the CPD course is completed.
An impurity was detected during stability monitoring. The impurity was isolated and the best estimate of identity indicated that the impurity is carprofen related.
The problem affects a limited number of batches and is identifiable through quality control testing. The concentration of the process impurity does not increase over time.
This recall is for the following batches only:
Norbrook is contacting wholesale dealers and veterinary surgeons to examine inventory and quarantine products subject to this recall.
For further information regarding the recall, contact Gary Mckee on 0044 2830 264435 or by email: gary.mckee@norbrook.co.uk
The hour-long webinar will be held on Tuesday 18th May from 7.30pm.
Chris is a European and RCVS Recognised Specialist in Equine Dentistry and the founding Director of the Equine Dental Clinic Ltd. Nicole is a European, American and RCVS Recognised Specialist in Equine Dentistry and is a co-director of the Equine Dental Clinic.
Chris and Nicole (pictured right) will discuss key points for examination, diagnostics and treatment, including:
Zoetis Equine Product Manager, Penny McCann said: "Chris Pearce and Nicole du Toit are known worldwide for their consulting, training, educating and CPD, as well as for running the longest established and largest equine veterinary dental specialist practice in Europe.
"We are delighted that they have agreed to share their knowledge with our client practices on 18th May and look forward to welcoming you."
To book your place for the webinar, visit: https://register.gotowebinar.com/register/173596806534344203
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 8034.
Animalcare has launched Vetaclean, a new range of disinfectants which the company says has a notably high kill activity against canine parvovirus and common feline viruses such as FIV, FeLV and FCV.
The range comprises Vetaclean Parvo Advance, a surface disinfectant-cleaner, Vetaclean enzymatic instrument detergent-cleaner, and an instrument disinfectant.
Animalcare Product Manager, Tony Liepman, said: "Veterinary nurses tell us that canine parvovirus is the most challenging and resistant pathogen they work with, and so we set this as our benchmark for the Vetaclean disinfectant products. Tested under EN protocols and having 99.99% + kill activity against parvovirus, our new disinfectants demonstrate high efficacy against a broad range of bacteria, including MRSA/MRSP, fungi, viruses, mycobacteria and spores.
"Infection control is in the spotlight at the moment, highlighted by initiatives from within and outside our industry. Firstly, the new Practice Standards Scheme - launched at the same time as our range - places great emphasis on having a rigorous biosecurity policy. This includes requirements for personal hygiene as well as cleanliness of premises and equipment. High-level decontamination of instruments and equipment is ensured through the Vetaclean two-stage process, which works with even soiled instruments or equipment, and in under 20 minutes. The products have also been designed to be suitable for use on the most specialised equipment seen in today’s practices, including flexible or rigid endoscopes, ultrasonic baths, aspirators, arthroscopes and re-processing machines.
"Importantly, the active ingredients in the Vetaclean range meet the criteria of the new EU Biocides Regulations, policed by the Health and Safety Executive in the UK, which came into effect on 1st September 2015. All products with biocidal activity now need to undergo a complex registration process, ensuring the products are not harmful to people, the environment or animals. The rigorous process may see many disinfectant manufacturers pull out of the market, resulting in less choice. Further, the Vetaclean range does not contain Poly (hexamethylene biguanide) hydrochloride (PHMB). The European Chemicals Agency (ECHA) is currently proposing that PHMB is listed as a category 2 carcinogen."
The Vetaclean Parvo Advance range includes a 1 litre lavender product in a self-dosing bottle, 5 litre apple and lemon-fragranced liquid concentrates and unfragranced large surface wipes. There are two different dilution rates: a general purpose dilution rate for most pathogens at 1:100 (10ml per litre), and a parvocidal dilution rate at 1:50 (20ml per litre). Animalcare says the alkaline-based formula ensures that the products are compatible with a wide range of materials and are non-staining. Both the enzymatic instrument cleaner and instrument disinfectant are available in 2 litre concentrates (incorporating a calibrated dosing reservoir).
The Vetaclean range is available now in wholesalers. The company has also produced a brochure Hygiene in practice, a guide to veterinary infection control from Animalcare, designed to help familiarise veterinary professionals with the principles and uses of the product range. There is also a special launch offer of Buy-4-Get-One-Free available from Animalcare representatives.
For further information, contact Animalcare on 01904 487687, or speak to your regional Animalcare representative: www.animalcare.co.uk/contact-us.
The range includes a spray, collars and diffusers.
Unlike many other pheromone diffusers which need to be plugged into a wall socket, Virbac's uses a patent-pending slow release technology which doesn't need power.
Virbac says the new range has been scientifically proven with published studies which demonstrate not only their effectiveness in managing stress-related behaviours in dogs and cats, but also an equivalent and superior efficacy to the current market leading pheromone products 1,2,3
Andrew Connolly, Virbac's Marketing Director for the UK and Ireland said: "Veterinary professionals have a crucial role to play in supporting their clients with the behavioural management of their pets, both when visiting the practice and at home, and the benefits of pheromones in helping to manage dog and cat behaviour are already very well recognised."
"With Zenidog and Zenifel we hope to make pheromone therapy easier, more cost-effective and better for the environment."
Zenidog and Zenifel are available to order from NVS, Covetrus and VSSCo now.
References
Buprecare is indicated for post-operative analgesia and the potentiation of the sedative effects of centrally-acting agents in dogs, as well as post-operative analgesia in cats.
It is presented in a 10 ml multi-use bottle.
Animalcare Product Manager Eleanor Workman Wright said: "Buprenorphine is a potent, high affinity, synthetic opioid.
"It plays a central role in many practice anaesthesia protocols so we are delighted to announce that it is back in stock."
For more information, contact your Animalcare Territory Manager or contact Animalcare’s head office on 01904 487687.
Achieved by VMG members who have demonstrated an ability to effectively manage a veterinary practice, hospital or unit, the CVPM is aimed at experienced managers and members of the veterinary team in a leadership or management role. The qualification tests the knowledge of candidates in areas including management, HR, communication, marketing and financial planning.
VMG Director Georgina Hills (pictured right) said: "Effective veterinary leaders require expertise in all aspects of running a successful business, as well as a deep understanding of the veterinary sector and the CVPM is unique in testing their knowledge across the board. It is increasingly recognised as a benchmark for excellence and we are delighted to have seen an uplift in applications last year."
Further details on the CVPM and the application form are available here: https://www.vetmg.com/education/cvpm/
People are invited to organise or join a walk to raise money for Canine Arthritis Management and its work to educate both dog owners and veterinary professionals about how even the smallest of changes can help to enhance the life of a dog with arthritis.
CAM highlights recent work from the Royal Veterinary College and University of Sydney through VetCompass, which highlighted some of the biggest welfare challenges facing our pet population including obesity, dental disease and osteoarthritis, with osteoarthritis identified as one of the most severe conditions.
Hannah said: "We need to start more conversations about arthritis; both dog owners and vets need to be more aware of the steps we can take to help prevent arthritis, and where dogs are affected, how we can take positive action to help them live fulfilled and comfortable lives."
Hannah says that arthritis is currently one of the biggest causes of owners choosing to euthanise their dogs, and she hopes that owners taking part in the walks will help spread the word that arthritis can be managed.
To find out more about the Big September Walks visit www.facebook.com/CAMBigSeptemberWalks
Dechra says the ability to split Prednicortone into 1.25 mg doses is particularly useful when used alongside Zycortal, the only licensed treatment for canine Addison’s disease in Europe.
Dechra Brand Manager Carol Morgan said: "Dogs with primary Addison’s disease have insufficient levels of natural mineralocorticoids (primarily aldosterone) and glucocorticoids (primarily cortisol). Zycortal contains DOCP, a synthetically produced steroid hormone, which acts in a similar way to aldosterone.
"It causes sodium retention and potassium excretion, helping to maintain water balance but Zycortal only replaces the mineralocorticoid. Therefore, a daily oral glucocorticoid treatment, such as Prednicortone, is needed to address the cortisol deficiency, alongside Zycortal.
"The amount of glucocorticoid administered should be adjusted to the individual dog’s need and it is likely that the dose required will be reduced over time."
She added that a combined approach of Zycortal and Prednicortone allowed independent dose titration of both mineralocorticoids and glucocorticoids.
"The advantage of prescribing the two treatments is that the dosage for each component can be tailored to an individual animal’s response. This leads to a reduction in the side effects usually associated with over-supplementation of glucocorticoids."
There are 250 tablets in a pack and Prednicortone offers accurate dosing using a double divisible SmartTab format and accurate dispensing via blister packs. The flavoured tablets also encourage easy oral administration.
For more information, visit www.dechra.co.uk.
Designed to help veterinary teams make clearer, more confident clinical decisions, the flowchart provides a step-by-step approach to diagnosing and managing ear disease in dogs and cats.
Renzo Di Florio, Technical Veterinary Adviser at Krka UK, said: “It takes you through each step, from diagnosis to treatment and long-term management, including identifying cases that might benefit from referral.
"It can also help practices to develop an otitis externa management plan protocol that’s useful for the whole team, and that’s practical and easy to integrate into existing workflows.”
One of the main messages in the flowchart is the central role of cytology in otitis management.
Tim said: “Cytology is essential to assess the level of inflammation and detect the presence of bacteria or Malassezia.
"This helps clinicians make informed decisions about whether antibiotics are truly needed.
"In contrast, culture and sensitivity testing can be misleading when used to guide topical therapy.”
https://www.krka.co.uk/veterinary-knowledge-hub
BSAVA Summit will take place from 16-17 December 2019 at the Royal College of Physicians in London and will involve a series of high-profile keynote speakers and interactive workshops.
The Association says the event will deliver CPD differently to other veterinary meetings, with most sessions run as facilitated workshops to enable delegates to lead and shape discussions.
Confirmed facilitators include RCVS CEO Lizzie Lockett, BEVA President Renate Weller, Director of Clinical Research and Excellence in Practice at VetPartners Rachel Dean and Small Animal Medicine Specialist and Advanced Practitioner in Veterinary Cardiology Dr Kit Sturgess. Each day delegates can choose three out of a total of five workshops. Online forums will be used in the run up to BSAVA Summit to develop ideas and thinking for the workshops before the event.
Day one will focus on ‘The Profession Today’ and topics will include workforce issues, telemedicine, specialism, the future of advanced practitioners and regulation of the profession.
Day two will explore the future of ‘The Profession Tomorrow’ with topics including communication, over-diagnosis, over-treatment and innovation.
On the Monday evening delegates, speakers and facilitators will be able to network at a drinks reception in the library at the Royal College of Physicians.
BSAVA President Sue Paterson said: "We have launched BSAVA Summit to address the rising demand for a space to debate important topics, challenge mindsets and question accepted benchmarks. Following feedback from our members and the profession, Summit will revolutionise veterinary conference norms with a free-flow approach to champion active debate, discussion and reflection.
"There is a growing need to tackle some of the ethical and professional problems that face vets today such as over diagnosis, the role of specialists in practice, and research in practice. Importantly, the format of the discussion forums means that whilst the debate is led by a facilitator, the delegates will drive the agenda to arrive at stimulating and satisfying outcomes. It has been designed to fit with the new outcomes-based approach proposed by the RCVS where veterinary professionals are encouraged to plan their CPD, do their CPD and reflect on what they have learnt.
"The delegates are the key to the event, and Summit should attract people who want to be involved, want to input, want to make a difference and want to help drive the profession forward. I already have people eagerly emailing me wanting news of when the registration goes live.
"Summit aims to help delegates take a hard look at the way they work. Our aim is for each delegate to set themselves personal goals and we will be following up in 3 months to see if they have achieved them."
The BSAVA says that although the Summit is primarily targeted at experienced small animal practitioners, all vets, including equine and large animal practitioners, are welcome to attend.
The full programme will be available and registration will open online on 17th June. BSAVA members will have an opportunity to book advance tickets, with general sale opening two weeks later.
For further information visit www.bsavasummit.com.
The PFMA says the factsheets have been produced with nutrition experts in response to demand from industry professionals.
Nicole Paley, Deputy Chief Executive, PFMA said: "We launched our factsheet range just over a year ago to tackle and dispel many of the myths around pet food. The range now covers sixteen subjects and with over 3,400 downloads, they have proved to be a valuable resource for pet professionals at the front line of pet care.
"We decided to add the Vegetarian Diets Factsheet and Food Allergy and Intolerance Factsheet to our range in response to demand for clarification on these topics. Owners are exploring alternative diets and whilst cats are obligate carnivores, dogs are omnivores and can adapt to vegetarian diets. As with all diets, they need to be well-balanced and our factsheet contains top tips.
"The Allergy Factsheet explains the difference between allergies and intolerances, which are both adverse food reactions but are very different conditions requiring different advice from veterinary professionals."
To see the full range of PFMA factsheets, visit: pfma.org.uk/fact-sheets.
Kellie Price, a Kent-based Registered Veterinary Nurse has been suspended from the Register for nine months by the RCVS RVN Disciplinary Committee after she admitted dishonestly creating four prescriptions, one of which was then fraudulently presented to a pharmacy.
The Committee heard that in January 2013, Miss Price, who did not attend the hearing and had no representation, had dishonestly created a prescription for two inhalers while working at a veterinary practice in Kent.
This prescription had been written and signed in the name of a locum veterinary surgeon, Cristiana Tudini MRCVS, without her knowledge or consent. The false prescription was subsequently presented to a pharmacy for dispensing.
In addition, in March 2013, Miss Price dishonestly created a further three prescriptions - one of which was written in the name of her colleague Cormac Higgins MRCVS, and two written in the name of Cristiana Tudini MRCVS without either's knowledge or consent. All four false prescriptions had been made out for Miss Price's Jack Russell terrier.
Upon discovering the false prescriptions, Mr Higgins asked Miss Price for an explanation and subsequently suspended her from her position pending further investigation. However, after being interviewed by Mr Higgins, she resigned before any in-house disciplinary hearing could take place. The allegations were then reported to both the RCVS and the police, the latter giving Miss Price a formal caution in respect of the false prescription made in January 2013.
In considering Miss Price's sanction, the RVN Disciplinary Committee took into account a number of aggravating and mitigating factors. In mitigation, it accepted Miss Price's explanation that, in the early hours of 6 January, she had suffered an asthma attack and that she had created the false prescription at work in a panic after realising her inhaler was empty and fearing a further asthma attack. The Committee also took into account a witness statement from Cormac Higgins MRCVS which described her as a "great nurse" and "good with patients and clients".
However, the Committee also considered aggravating factors including Miss Price's dishonesty and the fact that she then made further false prescriptions in March, although these were not then presented to a pharmacy.
Professor Noreen Burrows, who chaired the RVN Disciplinary Committee and spoke on its behalf, said: "The Committee is... satisfied that the admitted dishonesty amounts to disgraceful conduct in a professional respect [and] is satisfied that the respondent's conduct fell far short of the conduct to be expected of a registered veterinary nurse."
On deciding the sanction she added: "Taking into account all of the circumstances, the Committee has concluded that the suspension of the Respondent's name from the Register for a period of nine months is the proportionate sanction in this case."
The Committee's full findings and decision are available on the RCVS website (www.rcvs.org.uk/disciplinary).
The College highlights the following key changes:
The RCVS says the new corporate look is designed to be fresh, uncluttered and professional, and the new RCVS logo and strapline - "setting veterinary standards" - should leave visitors in no doubt as to the key purpose of the RCVS as a regulatory body. And whilst the new identity is modern in feel, the use of a shield device aims to maintain the link with the College's long history.
According to the College, the new brand was described by the veterinary surgeons and veterinary nurses who helped to develop it as "simple, clear and clean, with a strong message" and "modern and approachable".
President Peter Jinman said: "The College has been accused of being 'confused and confusing' in the past. With the new identity we have endeavoured to clarify that the College is a forward-thinking regulator - despite being established when Queen Victoria was only recently on the throne, and working to 45-year-old legislation.
"Changing the logo, font and colours we use is only a small part of the process though. Our branding review included several layers of research and we now have a better understanding of how we have been perceived, how we would like to be perceived, and what we need to do to get there. This includes changing how we behave and communicate as an organisation, as well as how we position ourselves to the outside world."
The new look, which includes new logos for RCVS Awards, the RCVS Charitable Trust and the Practice Standards Scheme, will be rolled out across other communications elements as the year unfolds, to avoid the unnecessary wastage of materials branded with the old identity.
Meanwhile, the website is a living medium, and the College says it is keen to hear feedback from users about what they like, and what could be improved, to help inform further developments.
The new suite offers chemotherapy and radiotherapy treatment facilities under one roof, including a linear accelerator (LINAC) which enables treatment of tumours previously considered untreatable.
Southfields has two full-time client-facing specialists in radiation oncology and two on-site, full-time double-boarded medical and radiation oncologists, along with dedicated radiotherapy technicians and therapeutic radiographers.
RCVS and European Specialist Sarah Mason, Southfield's lead in general oncology, said: “Southfields is already renowned as being the leader in cancer treatment for small animals in the UK and the opening of our dedicated oncology and radiotherapy suite takes patient care to an even higher level.”
www.southfields.co.uk
Last year Petplan received over 31,000 nominations across the five award categories: Practice of the Year, Vet of the Year, Vet Nurse of the Year, Practice Manager of the Year and Practice Support Staff of the Year.
The awards are judged by an independent panel which narrows the field to three finalists in each category, who are then invited to attend the awards ceremony.
The judges are looking for examples of exceptional levels of animal care, building and sustaining great relationships with colleagues and pet owners, and those who have gone above and beyond the call of duty.
James Barnes, Head of Sales & Partnerships at Petplan, said: “The Petplan Veterinary Awards provide the perfect opportunity to say thank you for the exceptional work carried out by members of the veterinary profession, whatever their field and wherever they’re based. The Petplan Vet Awards provide a great opportunity for both clients and colleagues to recognise the dedication and talent of veterinary professionals, teams and practices, right across the UK and say a particular thank you to those who have kept up the exceptional level of care even in the midst of a global crisis."
To nominate a colleague or your practice, visit www.petplan.co.uk before nominations close on 10th January 2022.
Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.
Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.
Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.
Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.
Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.
Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.
Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"
Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals. We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The London Vet Show will next take place on 11th and 12th November 2021 at the ExCeL Center, London.
CloserStill says the decision to cancel was made following several discussions with industry stakeholders, including partners, and considering the significant impact of both international and domestic travel.
Rob Chapman, MD of CloserStill’s veterinary portfolio, said: "COVID-19 has brought enormous pressures and uncertainty to the veterinary sector - both personally and professionally.
"Although the UK Government gave the green light for exhibitions and meetings to start again in October, after examining at the overall market and consultation with our partners, we feel the decision to postpone is in the best interest of the veterinary community.
"Although this news may be disappointing to those looking forward to the London Vet Show, unfortunately the coronavirus situation is continually developing. We want to be as clear and upfront as possible with our community and customers, and after careful consideration, our decision to reschedule was out of caution. As event organisers, the health and safety of our exhibitors, delegates, speakers, staff and supporters, is our number one priority."
"Obviously the postponement decision hasn’t been easy but we firmly believe it’s the right thing to do. We are so fortunate to have support of great partners like the Royal Veterinary College and the British Veterinary Association, along with the exhibitors, speakers and delegates we’ve spoken to so far; everyone has been really understanding. We can’t wait to see you all again virtually soon, and in person in 2021."
"The team and I are eager to continue to provide world-class education to veterinary professionals, to connect and encourage networking to foster the advancement of the veterinary sector. We are developing some great opportunities for the veterinary community come November. We will be announcing more details on this very soon."
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
Step 1: Clean with Oticare, a non-irritating, alcohol-free ceruminolytic ear cleaner formulated to keep ears hygienically clean and restore the normal microbiological balance of the ear canal. The product contains soothing essential oils and propylene glycol to moisturise the lining of the ear canal. It also contains a low concentration of lactic acid and salicylic acid.
Step 2: Treat with Aurimic (polymyxin B, miconazole and prednisolone acetate), which tackles the most common causes of otitis externa; e.g. Staphylococcus spp. and Malassezia. Animalcare says the proven synergistic effects of polymyxin B and miconazole1 allow the reduction of antibiotic concentration and help to minimise the probability of resistance.
Step 3: Prevent with new Oticurant, which Animalcare says is a completely new concept for maintaining healthy ears. Oticurant contains lactic acid to lower the pH, kaolin and lactose to absorb any additional moisture, and special sugars to prevent bacterial adherence to the skin in the ear canal. Oticurant is presented as an odourless mixture of fine powder in single dose sachets.
Tamsin Day, Veterinary Advisor at Animalcare, said: "This is a unique three step approach which we believe will give veterinary professionals more confidence in treating first line ear problems. The Super-earo’s represent a range of three products that together cover cleaning, treatment and prevention. Pet owners will find them easy to administer which will also help to keep these owners compliant to their treatment schedule."
For more information on the Super-earo’s contact your Animalcare representative or visit www.superearos.com
Reference